Choosing the right non-clinical CRO

Non-clinical contract research organisations (CROs) are an integral part of modern drug development. For any novel agent, delivery of GLP toxicity data to support clinical trials is a crucial step that requires a professional organisation with dedicated management, infrastructure and a broad array of technical and scientific skills. In selecting a CRO, the sponsor typically [...]

By |2018-09-12T14:07:14+00:00September 19th, 2018|Toxicology, Press|Comments Off on Choosing the right non-clinical CRO

Safety Must Be Prioritized In Drugs for Cancer

Despite the fact that the number of diagnosed cases of malignant mesothelioma are expected to rise in the next decades, there has been little real progress in available treatments, and the chemotherapy drug used to treat the disease is the same one that has been used for the last several  years. Though there is a [...]

By |2018-07-11T10:00:27+00:00May 16th, 2018|Press|Comments Off on Safety Must Be Prioritized In Drugs for Cancer

ApconiX Welcomes Dr Jane Barber to The Team

ApconiX is delighted to welcome Dr Jane Barber who joins us from AstraZeneca.  Jane, a dedicated drug discovery research scientist will work with the team of experts in nonclinical safety toxicology at ApconiX. Jane graduated from the University of Keele with a degree in Biology and Classical studies.  After researching Molecular Parasitology and Vector Biology, [...]

By |2018-08-23T10:56:48+00:00May 1st, 2018|Target Safety Assessments, Events|Comments Off on ApconiX Welcomes Dr Jane Barber to The Team

ApconiX Return Over 80% of hERG Screening Data to Clients Within One Week

Why is Time Critical to hERG Screening Data? ApconiX has worked hard to optimise our processes and is now returning over 80% of hERG screening data back to clients within one week of compound receipt.  This allows critical decisions to be made in medicinal chemistry on a full dataset of compound properties, avoiding mistakes and [...]

By |2018-07-19T16:25:00+00:00March 5th, 2018|Ion Channels|Comments Off on ApconiX Return Over 80% of hERG Screening Data to Clients Within One Week

Learning from Failure

Cardiovascular toxicity often hinders success – are companies picking the wrong compounds? Prolific novelist and academic CS Lewis once said, “Failures are finger posts on the road to achievement.” (Given pharma’s drug failure rate, the road ahead must truly be paved in gold.) When it comes to drug safety failure, toxicity – especially to the [...]

By |2018-07-11T15:26:46+00:00November 2nd, 2017|Ion Channels, Press|Comments Off on Learning from Failure